Please login to the form below

Not currently logged in
Email:
Password:

schizophrenia

This page shows the latest schizophrenia news and features for those working in and with pharma, biotech and healthcare.

Acadia’s Nuplazid misses the mark in major depressive disorder trial

Acadia’s Nuplazid misses the mark in major depressive disorder trial

Last year, the drug also failed a late-stage trial in schizophrenia inadequately controlled by currently-approved drugs. ... In this trial, Nuplazid was unable to show a significant improvement compared to placebo on the widely-used Positive and Negative

Latest news

More from news
Approximately 28 fully matching, plus 235 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    year. We’re talking about the lawsuits J&J is facing claiming damages as a result of using its products, including opioid painkillers, Baby Powder talc and its schizophrenia drug Risperdal

  • As the opioid crisis grabs the headlines, the search for safe treatments continues As the opioid crisis grabs the headlines, the search for safe treatments continues

    for opioid addiction, and the long-acting injectable Perseris for schizophrenia in adults, which got FDA approval this year. ... of other drugs that can make it difficult for schizophrenia patients to trust and adhere to regimes.

  • A new era of smart pharma A new era of smart pharma

    According to a systematic review of 39 studies, published in Clinical Psychology in 2002, a mean rate of medication non-adherence in schizophrenia sufferers is 41%, one of the highest of ... Furthermore, given the serious negative effects of

  • Tackling the challenge of non-adherence Tackling the challenge of non-adherence

    Rates of adherence are especially low among patients with chronic conditions such as COPD (33%), schizophrenia (52%) and asthma (67%). ... 80% in just five disease areas - asthma, type 2 diabetes, coronary heart disease, hypertension and schizophrenia -

  • Digital disruption Digital disruption

    Starting with projects in schizophrenia and Parkinson’s disease, Lundbeck and IBM will also work together to identify potential new drug targets and alternative indications.

More from intelligence
Approximately 1 fully matching, plus 17 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics